跳至主要内容
临床试验/NCT01240668
NCT01240668已完成不适用

An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization

Otsuka America Pharmaceutical79 个研究点 分布在 1 个国家目标入组 5,028 人开始时间: 2010年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
5,028
试验地点
79
主要终点
Time to initiation of hyponatremia treatment

研究概览

简要总结

The registry is a multi-center, prospective, observational study designed to collect data in patients with euvolemic and hypervolemic hyponatremia in the hospital setting in the USA and hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Europe; patients with hypovolemic hyponatremia will be excluded from the registry. The registry is observational in design, and the registry will collect data on patients with a serum sodium ≤130 mmol/L. Data from the patients' chart will be collected throughout the duration of the hospital, from admission to discharge, and the data will be entered into the case report form (CRF) or into an electronic data capture (EDC) system. These patients will be entered into the registry over the duration of 18 months at community, tertiary, and academic medical centers from diverse multiple regions of the USA and Europe.

A patient's treatment will be determined by their caregiver and not by this protocol. Thus, the registry will provide a unique opportunity to evaluate how the patients are managed under real-world management conditions.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults ≥18 years old who are hospitalized
  • Euvolemic or hypervolemic hyponatremia with serum sodium ≤130mmol/L
  • For euvolemic hyponatremia:
  • Euvolemia is defined as: absence of clinical and historical evidence of extracellular fluid volume depletion or sequestration; and absence of edema and ascites; or
  • Physician diagnosis of SIADH
  • For hypervolemic hyponatremia (applies to USA sites only):
  • Hypervolemia is defined as: excess extracellular fluid volume manifesting as dependent edema or ascites
  • Patients may have one or more of the following underlying co-morbid conditions:
  • Congestive heart failure
  • Cirrhosis and/or liver failure
  • Nephrotic syndrome

排除标准

  • Patients with hypovolemic hyponatremia
  • Use of investigational drug, biologic, or device during the study

结局指标

主要结局

Time to initiation of hyponatremia treatment

时间窗: Hospital Discharge

Duration of hospital stay from time of first presentation of hyponatremia (which will be taken as the time of first presentation of hyponatremia for the current admission) to discharge

时间窗: Hospital Discharge

Change in serum sodium concentration from beginning of treatment period to the end of treatment period or discharge for a given hyponatremia treatment

时间窗: Hospital Discharge

次要结局

  • Medically necessary length of hospital stay and duration of intensive care unit (ICU) stay(Hospital Discharge)
  • Relative proportions of etiologies associated with hyponatremia(Hospital Discharge)
  • Effectiveness of individual therapies in correcting hyponatremia and time taken to achieve the correction.(Hospital Discharge)
  • Impact of hyponatremia on medically necessary length of stay(Hospital Discharge)
  • Therapies used in the management of hyponatremia(Hospital Discharge)
  • Profile of investigations performed in diagnosing hyponatremia(Hospital Discharge)
  • Effectiveness of individual therapies in achieving symptom improvement measured as the number of reported symptoms at the start and end of treatment with a specific therapy(Hospital Discharge)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (79)

Loading locations...

相似试验